Low-molecular-weight heparin: Biochemistry, pharmacology, and concurrent drug precautions

Regional Anesthesia and Pain Medicine

Volumn 23, Issue 6 SUPPL. 2, 1998, Pages 135-139

  Heit, John A ^a,b  

^a Section of Vascular Medicine

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARDEPARIN; CLOPIDOGREL; DALTEPARIN; DANAPAROID; ENOXAPARIN; HEPARIN DERIVATIVE; HEPARINOID; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; TICLOPIDINE;

ANTICOAGULATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BINDING; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; HUMAN; MOLECULAR WEIGHT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REGIONAL ANESTHESIA; REVIEW; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ANESTHESIA, CONDUCTION; ANTICOAGULANTS; BIOCHEMISTRY; DRUG INTERACTIONS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPARINOIDS; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 0031741595     PISSN: 0146521X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Hirsh J, Levine MN. Low molecular weight heparin: Laboratory properties and clinical evaluation. Eur J Surg 1994: 571 (suppl): 9-22.
2. Salzman EW, Rosenberg RC, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980: 65: 64-73.
3. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995: 332: 1330-1335.
4. Ramakrishna R, Manoharan A, Kwan YL, Kyle PW. Heparin-induced thrombocytopenia: Cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran). Br J Haematol 1995: 91: 736-738.
5. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AWA. Low molecular weight heparin: A critical analysis of clinical trials. Pharmacol Rev 1994: 46: 89-109.
6. Spiro TE, Johnson GJ, Christie MH, et al. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery. Ann Intern Med 1994: 121: 81-89.
7. Colwell CE, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg 1994: 76A: 3-14.
8. Colwell CW, Spiro TE, Trowbridge AA, Stephens JWG, Gardiner GA, Ritter MA, for the Enoxaparin Clinical Trial Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep venous thrombosis after elective knee arthroplasty. Clin Orthop 1995: 321: 19-27.
9. Planes A, Vochelle N, Darmon J-Y, Fagolla M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin and placebo. Lancet 1996: 348: 28-31.
10. Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: A double-blind, dose-ranging study. Thromb Haemost 1997: 77: 32-38.
11. Francis CW, Pellegrini VD, Totterman S, Boyd AD, Marder VJ, Liebert KM, Stulberg BN, Ayers DC, Rosenberg A, Kessler C, Johanson NA. Prevention of deep-vein thrombosis after total hip arthroplasty: Comparison of warfarin and dalteparin. J Bone Joint Surg 1997: 79A: 1365-1372.
12. Cade JF, Buchanan MR, Boneu B, et al. A comparison of the antithrombotic and hemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 1984: 35: 613-625.
13. Patrono C, Coller B, Dalen J, FitzGerald GA, et al. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Fifth ACCP Conference on Antithrombotic Therapy. Chest 1998: in press.
14. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992: 79: 1-17.
15. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip of knee arthroplasty. J Bone Joint Surg 1994: 76A: 1174-1185.
16. Dahl OE, Andreassen G, Aspelin T, Müller C, Mathiesen P, Nyhus S, Abdelnoor M, Solhaug J-H, Arnesen H. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997: 77: 26-31.
17. Hoek J, Nurmohamed MT, Hamelynck KJ, Marti RK, Knipscheer HC, ten Cate H, Büller HR, Magnani HN, ten Cate JW. Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost 1992: 67: 28-32.
18. Leclerc JR, Geerts WH, Desjardins L, Jobin F, Laroche F, Delorme F, Haviernick S, Atkinson S, Bourgouin J. Prevention of deep vein thrombosis after major knee surgery: A randomized, double-blind trial comparing a low molecular weight heparin fragment (enoxaparin) to placebo. Thromb Haemost 1992: 67: 417-423.
19. Hull RD, Raskob GE, Pineo GF, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, Elliott CG, Panju A, Brant R. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993: 329: 1370-1376.
20. Leclerc JR, Geerts WH, Desjardins L, Laflamme H, l'Espérance, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F. Prevention of venous thromboembolism after knee arthroplasty: A randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 1996: 124: 619-626.
21. Gent M, Hirsh J, Ginsberg JS, Powers PJ, Levine MN, Geerts WH, Jay RM, Leclerc J, Neemeh JA, Turpie AGG. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 1996: 93: 80-84.
22. Leyvraz P, Bachmann F, Bohnet J, Breyer HG, Estoppey D, Haas S, Hochreiter J, Jakubek H, Mair J, Sorenson R, Stiekema J. Thromboembolic prophylaxis in total hip replacement: A comparison between the low molecular weight heparinoid lomoparan and heparin-dihydroergotamine. Br J Surg 1992: 79: 911-914.